Sarepta Therapeutics, Inc. (SRPT) Analysts See $-0.57 EPS

June 16, 2018 - By Ash

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It dropped, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Dekabank Deutsche Girozentrale accumulated 0.01% or 29,400 shares. Wellington Mngmt Limited Liability Partnership holds 0% or 15,981 shares. Great West Life Assurance Can holds 6,948 shares. Rock Springs Cap Ltd Partnership invested 0.82% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Jane Street Limited Liability stated it has 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). California Employees Retirement Systems has invested 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Atika Cap Mgmt Lc invested in 2.46% or 97,000 shares. The Virginia-based Quantitative Inv Mgmt Limited Liability has invested 0.19% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Fisher Asset Ltd Liability Co reported 57,431 shares. Sphera Funds holds 248,997 shares. First Allied Advisory Service invested in 7,064 shares. Tekla Cap Management Limited Liability Com owns 378,516 shares or 1.09% of their US portfolio. Quantitative Systematic Strategies Ltd Liability Corporation reported 0.06% stake. Lehman Financial Res invested in 0.24% or 6,442 shares. Smith Asset Gp Limited Partnership reported 5,060 shares stake.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock increased 3.55% or $3.51 during the last trading session, reaching $102.29. About 1.91M shares traded or 49.53% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 17, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 17 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 28 analyst reports since January 3, 2018 according to SRatingsIntel. JP Morgan maintained the shares of SRPT in report on Wednesday, March 14 with “Overweight” rating. J.P. Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, February 21. J.P. Morgan has “Buy” rating and $75.0 target. The company was upgraded on Friday, May 11 by Barclays Capital. The firm has “Buy” rating given on Tuesday, May 15 by Leerink Swann. The rating was initiated by Janney Capital on Wednesday, January 3 with “Buy”. RBC Capital Markets initiated the shares of SRPT in report on Monday, January 22 with “Buy” rating. The company was maintained on Friday, May 4 by Credit Suisse. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Tuesday, June 5 by Nomura. The firm has “Buy” rating given on Monday, March 12 by H.C. Wainwright. Morgan Stanley downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, March 21 to “Equal-Weight” rating.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.70 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Sarepta Therapeutics to Present at Two Upcoming Investor Conferences” on June 05, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” published on June 13, 2018, Streetinsider.com published: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” on June 13, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Biotech ETFs Are the Best Way to Play the Recovering Sector” published on May 30, 2018 as well as Seekingalpha.com‘s news article titled: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” with publication date: June 01, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.